Craig-Hallum Initiates Quoin Pharmaceuticals at Buy Rating
Craig-Hallum analysts have started coverage of Quoin Pharmaceuticals shares with a Buy rating, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that analysts at Craig-Hallum have begun coverage of Quoin Pharmaceuticals (QNRX) and assigned the shares a Buy rating.
The report does not include the reasoning behind the rating or a price target. It only links to the Benzinga ratings page for the stock.
why it matters
Initial coverage from smaller brokerage firms on little-known biotech issuers usually affects the stock in question rather than the broader market. The analyst's full report would be needed to understand the valuation logic.
tags
instruments
sources
- Quoin Pharmaceuticals Initiated at Buy by Craig-Hallum — Dow Jones Newswires, 20 November 2026 at 18:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗